System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42540060 DOI: 10.1016/j.ero.2025.11.010

Canakinumab for systemic-onset juvenile idiopathic arthritis/Still's disease-effectiveness and safety data from the BiKeR registry.

EULAR Rheumatol Open 2(2):100083

Authors: Gerd Horneff, Tilmann Kallinich, Kirsten Minden, Frank Dressler, Markus Hufnagel, Frank Weller-Heinemann, Ariane Klein

Affiliations

  • Department of General Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
  • Department of Paediatric and Adolescent Medicine, University Hospital of Cologne, Cologne, Germany.
  • Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany.
  • Deutsches Rheuma-Forschungszentrum Berlin, Leibniz Institute, Berlin, Germany.
  • Division of Paediatric Pneumology, Allergology and Neonatology, Department of Paediatric and Adolescent Medicine, Medizinische Hochschule Hannover, Hannover, Germany.
  • Division of Paediatric Infectious Diseases and Rheumatology, Department of Paediatric and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
  • Paediatric Rheumatology, Department of Paediatrics and Adolescent Medicine, Eltern-Kind-Zentrum Prof. Hess, Klinikum Bremen Mitte, Bremen, Germany.

Abstract

OBJECTIVES

In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still's disease. This study assesses the experience of sJIA/Still's disease patients treated with canakinumab in clinical practice.

METHODS

Data of 79 sJIA/Still's disease patients extracted from the BiKeR registry included patients' and disease characteristics. Three subgroups with disease durations before canakinumab initiation of ≤3 months, >3 to ≤12 months, and >12 months were compared, and 2 with canakinumab as first- and second- or more-line treatment.

RESULTS

Disease duration was ≤3 months before canakinumab initiation for 26 patients, >3 to ≤12 months for 24 patients, and >12 months for 29 patients. Thirty-nine patients received canakinumab as first-line treatment and 40 as second- or more-line treatment. Disease severity as assessed by the systemic Juvenile Arthritis Disease Activity Score-10 (sJADAS10) was highest for patients with a disease duration <3 months before canakinumab initiation. In the total cohort, after 3, 6, 12, 18, and 24 months, 86%, 81%, 81%, 75%, and 87% of patients reached inactive disease, respectively. Numerically, more patients reached the treatment goal of inactive disease when the disease duration was shorter before initiation of canakinumab. Minimal disease activity (sJADAS10 ≤6.0) did not differ among subgroups. Compared with second-line, more patients with first-line treatment reached inactive disease at months 6, 12, and 24 after canakinumab initiation. sJADAS10 at 12 months correlated significantly with disease duration before treatment.

CONCLUSIONS

Canakinumab treatment led to high improvement rates and achievement of inactive disease state, particularly if they are administered early. Data from clinical practice confirm clinical study data.

MeSH

Registries, Safety, Arthritis, Therapeutics, Arthritis, Juvenile